Companies Y-mAbs Therapeutics, Inc.
Y-mAbs Therapeutics (YMAB): executive pay, fiscal 2024
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Y-mAbs Therapeutics, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers56th pct.Of 19 peer CEOs
CEO pay, last three years
- $3,110,553FY2023
- $4,557,590FY2024
CEO total pay was $4,557,590 in fiscal 2024, up from $3,110,553 in fiscal 2023.
FY2024: salary $705,600 · bonus $0 · stock awards $1,170,732 · option awards $2,288,662
Executives and directors
Peter Pfreundschuh · CFOMichael Rossi · CEOThomas Gad · ExecutiveAshutosh Tyagi · Independent DirectorDavid N. Gill · Independent DirectorDr. Gérard Ber · Former director (through FY2024)James I. Healy · Chair of the BoardJohan Wedell-Wedellsborg · Independent DirectorLaura J. Hamill · Independent DirectorMary Tagliaferri · Independent Director
Frequently asked questions
Who was the highest-paid executive at Y-mAbs Therapeutics, Inc. in fiscal 2024?
As disclosed, Michael Rossi (President and Chief Executive Officer) was the highest-paid executive at Y-mAbs Therapeutics, Inc. in fiscal 2024, with total compensation of $4,557,590.
How does Y-mAbs Therapeutics, Inc.'s chief executive pay compare to its disclosed peer group?
As disclosed, Michael Rossi's total compensation ranked at the 56th percentile of Y-mAbs Therapeutics, Inc.'s disclosed peer group.
How did shareholders vote on Y-mAbs Therapeutics, Inc.'s executive compensation?
As disclosed, 87.56% of shareholders supported Y-mAbs Therapeutics, Inc.'s executive compensation in the latest say-on-pay vote.
How much does Y-mAbs Therapeutics, Inc. spend in total on board compensation for fiscal 2024?
As disclosed, Y-mAbs Therapeutics, Inc. reported total board compensation of $765,691 for fiscal 2024.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Michael Rossi | $705,600 | $0 | $1,170,732 | $2,288,662 | $392,596 | $0 | $0 | $4,557,590 |
| President and Chief Executive Officer | ||||||||
| Peter Pfreundschuh | 252,083 | 0 | 573,620 | 1,580,609 | 98,405 | 0 | 0 | 2,504,717 |
| Treasurer and Chief Financial Officer | ||||||||
| Thomas Gad | 579,752 | 0 | 213,928 | 949,349 | 248,134 | 0 | 84,000 | 2,075,163 |
| Founder, Chief Business Officer and Vice Chairman of the Board of Directors | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2024 total | FY2023 total | FY2022 total | Δ FY2023→2024 |
|---|---|---|---|---|
| Michael Rossi | $4,557,590 | $3,110,553 | — | ↑ +1,447,037 |
| Peter Pfreundschuh | 2,504,717 | — | — | — |
| Thomas Gad | 2,075,163 | 2,454,483 | — | ↓ −379,320 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The Company's executive pay program is consistent with market and industry practice and reflects a pay-for-performance philosophy.
| CEO STI target (% of salary) | 65% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2024
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Thomas Gad | Option | 21,288 | 9.52 | — |
| Thomas Gad | RSU | 22,100 | — | 173,043 |
| Thomas Gad | RSU | 27,001 | — | 211,418 |
| Thomas Gad | Option | 27,588 | 15.73 | — |
| Michael Rossi | RSU | 35,700 | — | 279,531 |
| Peter Pfreundschuh | RSU | 46,000 | — | 360,180 |
| Michael Rossi | PSU | 54,000 | — | 422,820 |
| Thomas Gad | Option | 54,690 | 5.75 | — |
| Thomas Gad | Option | 126,235 | 4.7 | — |
| Thomas Gad | Option | 132,500 | 9.83 | — |
| Michael Rossi | Option | 214,200 | 14.36 | — |
| Michael Rossi | Option | 448,634 | 5.75 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Mary TagliaferriIndependent · Compensation · Not standing for re-election | $31,301 | $116,954 | $454,242 | — | $0 | $602,497 |
| James I. HealyIndependent · Board Chair · Audit | 95,000 | 41,975 | 125,817 | — | 0 | 262,792 |
| David N. GillIndependent · Audit (Chair) · Compensation · Nominating and Corporate Governance | 82,500 | 41,975 | 125,817 | — | 0 | 250,292 |
| Laura J. HamillIndependent · Compensation (Chair) · Nominating and Corporate Governance | 70,000 | 41,975 | 125,817 | — | 0 | 237,792 |
| Ashutosh TyagiIndependent · Nominating and Corporate Governance | 60,000 | 41,975 | 125,817 | — | 0 | 227,792 |
| Johan Wedell-WedellsborgIndependent · Audit · Nominating and Corporate Governance (Chair) | 60,000 | 41,975 | 125,817 | — | 0 | 227,792 |
| Dr. Gérard BerIndependent · Departed during FY | 40,061 | 0 | 0 | — | 0 | 40,061 |
| Thomas GadEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Michael RossiEmployee director | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | $127,500 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2024 |
|---|---|
| Cash retainers and fees | $438,862 |
| Equity awards (grant-date value) | $326,829 |
| All other compensation | $0 |
| Total cost of the board | $765,691 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Y-mAbs Therapeutics as a peer
Companies that benchmark against YMAB
13 companies name YMAB as a compensation peer
The list of companies that name YMAB as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2024
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
ATRA Atara Biotherapeutics, Inc.AGIO Agios Pharmaceuticals, Inc.GTHX G1 Therapeutics, Inc.IOVA Iovance Biotherapeutics, Inc.WHWK Aadi Bioscience, Inc.RCUS Arcus Biosciences, Inc.BCRX BioCryst Pharmaceuticals, Inc.BLUE bluebird bio, Inc.DCPH Deciphera Pharmaceuticals, Inc.HRTX Heron Therapeutics, Inc.KPTI Karyopharm Therapeutics Inc.MGNX MacroGenics, Inc.PBYI Puma Biotechnology, Inc.RYTM Rhythm Pharmaceuticals, Inc.RIGL Rigel Pharmaceuticals, Inc.SWTX SpringWorks Therapeutics, Inc.TVTX Travere Therapeutics, Inc.URGN UroGen Pharma Ltd. Typically
Peer reciprocity
The companies Y-mAbs Therapeutics, Inc. names as compensation peers that name it back in their own disclosed peer groups.
G1 Therapeutics, Inc. (GTHX)151Deciphera Pharmaceuticals, Inc. (DCPH)152Heron Therapeutics, Inc. (HRTX)153MacroGenics, Inc. (MGNX)154UroGen Pharma Ltd. (URGN)155
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Rhythm Pharmaceuticals, Inc. | 2025 | David Meeker | $807,692 | $8,274,785 | $7,688,560 | $759,488 | $17,544,525 |
| 2 | SpringWorks Therapeutics, Inc. | 2024 | Saqib Islam | 760,000 | 7,899,760 | 6,689,100 | 798,000 | 16,153,317 |
| 3 | BioCryst Pharmaceuticals, Inc. | 2025 | Jon Stonehouse | 728,466 | 0 | 11,132,458 | 1,052,633 | 12,951,082 |
| 4 | Arcus Biosciences, Inc. | 2025 | Terry Rosen | 775,000 | 2,199,450 | 6,008,860 | 658,750 | 9,656,813 |
| 5 | Travere Therapeutics, Inc. | 2025 | Eric Dube | 854,250 | 3,314,520 | 3,309,384 | 964,125 | 8,457,151 |
| 6 | Deciphera Pharmaceuticals, Inc. | 2023 | Steven Hoerter | 738,200 | 1,935,000 | 2,837,100 | 487,212 | 6,010,712 |
| 7 | Agios Pharmaceuticals, Inc. | 2025 | Brian Goff | 846,864 | 1,291,680 | 2,627,252 | 592,804 | 5,370,389 |
| 8 | Rigel Pharmaceuticals, Inc. | 2025 | Raul Rodriguez | 787,405 | 951,327 | 2,241,570 | 634,649 | 4,658,805 |
| 9 | Y-mAbs Therapeutics, Inc. | 2024 | Michael Rossi | 705,600 | 1,170,732 | 2,288,662 | 392,596 | 4,557,590 |
| 10 | UroGen Pharma Ltd. | 2025 | Elizabeth Barrett | 855,590 | 2,122,211 | 0 | 516,263 | 4,310,624 |
| 11 | Heron Therapeutics, Inc. | 2025 | Craig Collard | 689,431 | 946,254 | 1,352,917 | 517,189 | 3,516,291 |
| 12 | Aadi Bioscience, Inc. | 2025 | David Lennon | 676,504 | 1,318,907 | 973,664 | 0 | 3,359,075 |
| 13 | G1 Therapeutics, Inc. | 2023 | John Bailey | 794,976 | 1,392,022 | 666,209 | 387,551 | 3,250,658 |
| 14 | Puma Biotechnology, Inc. | 2025 | Alan Auerbach | 931,333 | 551,549 | 535,513 | 1,027,307 | 3,062,337 |
| 15 | bluebird bio, Inc. | 2023 | Andrew Obenshain | 681,657 | 863,590 | 1,142,440 | 348,024 | 3,049,181 |
| 16 | Karyopharm Therapeutics Inc. | 2025 | Richard Paulson | 770,000 | 838,996 | 241,544 | 350,350 | 2,320,902 |
| 17 | MacroGenics, Inc. | 2025 | Eric Risser | 561,568 | 52,000 | 1,049,386 | 251,900 | 2,078,854 |
| 18 | Iovance Biotherapeutics, Inc. | 2025 | Frederick Vogt | 800,000 | 759,375 | 0 | 312,000 | 1,888,175 |
| 19 | Atara Biotherapeutics, Inc. | 2025 | AnhCo Nguyen | 668,800 | 0 | 0 | 0 | 1,068,069 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Y-mAbs Therapeutics, Inc. | 85.6% | not disclosed | No | Aon |
| Aadi Bioscience, Inc. | not disclosed | not disclosed | not disclosed | Radford |
| Agios Pharmaceuticals, Inc. | 100% | Option 40 · PSU 40 · RSU 20 | No | Aon |
| Arcus Biosciences, Inc. | 100% | Options 67 · RSU 33 | not disclosed | Radford |
| Atara Biotherapeutics, Inc. | not disclosed | RSU 100 | not disclosed | Pearl Meyer |
| BioCryst Pharmaceuticals, Inc. | not disclosed | not disclosed | not disclosed | Aon |
| bluebird bio, Inc. | 85% | Options 50 · RSU 50 | No | Aon |
| Deciphera Pharmaceuticals, Inc. | 110% | Option 50 · PSU 50 · RSU 25 | No | Pearl Meyer & Partners, LLC |
| G1 Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Radford, Aon’s Human Capital Solutions Practice |
| Heron Therapeutics, Inc. | not disclosed | Option 66.67 · RSU 33.33 | not disclosed | Compensia, Inc. |
| Iovance Biotherapeutics, Inc. | 60% | not disclosed | No | Haigh & Company |
| Karyopharm Therapeutics Inc. | 90% | not disclosed | Yes — Relative TSR | Alpine, WTW |
| MacroGenics, Inc. | 85% | not disclosed | not disclosed | Alpine Rewards, LLC |
| Puma Biotechnology, Inc. | 169.7% | Options 50 · RSU 50 | not disclosed | Compensia |
| Rhythm Pharmaceuticals, Inc. | 120% | Options 50 · RSU 50 | No | Pay Governance |
| Rigel Pharmaceuticals, Inc. | 124% | Options 75 · RSU 25 | No | Pearl Meyer |
| SpringWorks Therapeutics, Inc. | 140% | not disclosed | Yes — Relative Total Shareholder Return (TSR) | Aon |
| Travere Therapeutics, Inc. | 150% | not disclosed | No | Aon |
| UroGen Pharma Ltd. | 80% | RSU 50 · PSU 50 | No | Compensia, Inc. |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2025 | 2025-07-11 | 27,011,027 | 3,838,565 | 1,755 | 87.56% | Passed |
| 2024 | 2024-06-11 | 27,772,834 | 721,693 | 521 | 97.47% | Passed |
| 2023 | 2023-06-08 | 15,934,564 | 5,999,462 | 8,132 | 72.65% | Passed |
| 2022 | 2022-06-09 | 15,782,697 | 11,179,894 | 534,109 | 58.54% | Passed |
| 2021 | 2021-06-10 | 20,503,309 | 10,933,563 | 1,225 | 65.22% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2025 | 2025-07-11 | 87.56%a |
| 2024 | 2024-06-11 | 97.47%b |
| 2023 | 2023-06-08 | 72.65%c |
a. Voting standard not stated in the filing.
b. Approved under the standard stated in the filing — “If you ABSTAIN from voting on Proposal No. 3, the abstention will have no effect on the outcome of the proposal.”.
c. Approved under the standard stated in the filing — “If you ABSTAIN from voting on Proposal No. 3, the abstention will have the same effect as a vote AGAINST such proposal.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2024 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Thomas Gad | Director | 2025-06-03 | A | 103,000 | $2 | $206,000 | Common | Form 4 ↗ |
| Thomas Gad | Director | 2025-06-03 | D | 103,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ashutosh Tyagi | Director | 2025-06-30 | A | 33,450 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ashutosh Tyagi | Director | 2025-06-30 | A | 25,080 | 0 | 0 | Common | Form 4 ↗ |
| James I. Healy | Director | 2025-06-30 | A | 33,450 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Johan Wedell-Wedellsborg | Director | 2025-06-30 | A | 33,450 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David N. Gill | Director | 2025-06-30 | A | 33,450 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David N. Gill | Director | 2025-06-30 | A | 25,080 | 0 | 0 | Common | Form 4 ↗ |
| James I. Healy | Director | 2025-06-30 | A | 25,080 | 0 | 0 | Common | Form 4 ↗ |
| Johan Wedell-Wedellsborg | Director | 2025-06-30 | A | 25,080 | 0 | 0 | Common | Form 4 ↗ |
| Laura J. Hamill | Director | 2025-06-30 | A | 33,450 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Laura J. Hamill | Director | 2025-06-30 | A | 25,080 | 0 | 0 | Common | Form 4 ↗ |
| Michael Rossi | Director | 2025-09-16 | D | 18,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ashutosh Tyagi | Director | 2025-09-16 | D | 14,545 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ashutosh Tyagi | Director | 2025-09-16 | D | 13,950 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Rossi | Director | 2025-09-16 | D | 52,650 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James I. Healy | Director | 2025-09-16 | D | 33,450 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James I. Healy | Director | 2025-09-16 | D | 14,545 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James I. Healy | Director | 2025-09-16 | D | 13,950 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James I. Healy | Director | 2025-09-16 | D | 11,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James I. Healy | Director | 2025-09-16 | D | 11,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James I. Healy | Director | 2025-09-16 | D | 8,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James I. Healy | Director | 2025-09-16 | D | 14,222 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James I. Healy | Director | 2025-09-16 | D | 2,194,278 | 9 | 18,870,791 | Common, indirect | Form 4 ↗ |
| James I. Healy | Director | 2025-09-16 | D | 31,603 | 9 | 271,786 | Common | Form 4 ↗ |
| John LaRocca | SVP, General Counsel & Secry | 2025-09-16 | D | 42,900 | — | — | Derivative, Class A Common | Form 4 ↗ |
| John LaRocca | SVP, General Counsel & Secry | 2025-09-16 | D | 142,600 | — | — | Derivative, Class A Common | Form 4 ↗ |
| John LaRocca | SVP, General Counsel & Secry | 2025-09-16 | D | 21,500 | — | — | Common | Form 4 ↗ |
| Johan Wedell-Wedellsborg | Director | 2025-09-16 | D | 33,450 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Johan Wedell-Wedellsborg | Director | 2025-09-16 | D | 14,545 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Johan Wedell-Wedellsborg | Director | 2025-09-16 | D | 13,950 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Johan Wedell-Wedellsborg | Director | 2025-09-16 | D | 16,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Johan Wedell-Wedellsborg | Director | 2025-09-16 | D | 11,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Johan Wedell-Wedellsborg | Director | 2025-09-16 | D | 11,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Johan Wedell-Wedellsborg | Director | 2025-09-16 | D | 16,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Johan Wedell-Wedellsborg | Director | 2025-09-16 | D | 32,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Johan Wedell-Wedellsborg | Director | 2025-09-16 | D | 36,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Johan Wedell-Wedellsborg | Director | 2025-09-16 | D | 4,559,233 | 9 | 39,209,404 | Common | Form 4 ↗ |
| Johan Wedell-Wedellsborg | Director | 2025-09-16 | D | 25,080 | — | — | Common | Form 4 ↗ |
| Johan Wedell-Wedellsborg | Director | 2025-09-16 | D | 5,825 | 9 | 50,095 | Common | Form 4 ↗ |
| Joris Wilms | SVP & Chief Operating Officer | 2025-09-16 | D | 42,900 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Joris Wilms | SVP & Chief Operating Officer | 2025-09-16 | D | 35,700 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Joris Wilms | SVP & Chief Operating Officer | 2025-09-16 | D | 32,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Joris Wilms | SVP & Chief Operating Officer | 2025-09-16 | D | 35,700 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Joris Wilms | SVP & Chief Operating Officer | 2025-09-16 | D | 20,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Joris Wilms | SVP & Chief Operating Officer | 2025-09-16 | D | 32,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Laura J. Hamill | Director | 2025-09-16 | D | 5,825 | 9 | 50,095 | Common | Form 4 ↗ |
| Joris Wilms | SVP & Chief Operating Officer | 2025-09-16 | D | 20,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Rossi | Director | 2025-09-16 | D | 18,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Rossi | Director | 2025-09-16 | D | 129,101 | — | — | Common | Form 4 ↗ |
| Michael Rossi | Director | 2025-09-16 | D | 7,982 | 9 | 68,645 | Common | Form 4 ↗ |
| Thomas Gad | Director | 2025-09-16 | D | 91,450 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ashutosh Tyagi | Director | 2025-09-16 | D | 33,450 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ashutosh Tyagi | Director | 2025-09-16 | D | 11,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ashutosh Tyagi | Director | 2025-09-16 | D | 11,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ashutosh Tyagi | Director | 2025-09-16 | D | 32,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ashutosh Tyagi | Director | 2025-09-16 | D | 16,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Douglas J. Gentilcore | SVP, Danyelza Bus. Unit Head | 2025-09-16 | D | 142,600 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Biotech ApS WG | Director | 2025-09-16 | D | 4,559,233 | 9 | 39,209,404 | Common | Form 4 ↗ |
| Joris Wilms | SVP & Chief Operating Officer | 2025-09-16 | D | 20,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Joris Wilms | SVP & Chief Operating Officer | 2025-09-16 | D | 20,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Joris Wilms | SVP & Chief Operating Officer | 2025-09-16 | D | 20,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Joris Wilms | SVP & Chief Operating Officer | 2025-09-16 | D | 20,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Joris Wilms | SVP & Chief Operating Officer | 2025-09-16 | D | 39,301 | — | — | Common | Form 4 ↗ |
| Joris Wilms | SVP & Chief Operating Officer | 2025-09-16 | D | 12,799 | 9 | 110,071 | Common | Form 4 ↗ |
| Ashutosh Tyagi | Director | 2025-09-16 | D | 16,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ashutosh Tyagi | Director | 2025-09-16 | D | 25,080 | — | — | Common | Form 4 ↗ |
| Ashutosh Tyagi | Director | 2025-09-16 | D | 5,825 | 9 | 50,095 | Common | Form 4 ↗ |
| Thomas Gad | Director | 2025-09-16 | D | 16,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Thomas Gad | Director | 2025-09-16 | D | 16,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Thomas Gad | Director | 2025-09-16 | D | 64,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Thomas Gad | Director | 2025-09-16 | D | 132,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Thomas Gad | Director | 2025-09-16 | D | 75,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Thomas Gad | Director | 2025-09-16 | D | 242,200 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Thomas Gad | Director | 2025-09-16 | D | 60,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Thomas Gad | Director | 2025-09-16 | D | 110,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Thomas Gad | Director | 2025-09-16 | D | 107,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Thomas Gad | Director | 2025-09-16 | D | 100,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Thomas Gad | Director | 2025-09-16 | D | 16,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Thomas Gad | Director | 2025-09-16 | D | 143,169 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Thomas Gad | Director | 2025-09-16 | D | 60,000 | 9 | 516,000 | Common | Form 4 ↗ |
| Thomas Gad | Director | 2025-09-16 | D | 67,681 | 9 | 582,057 | Common | Form 4 ↗ |
| Thomas Gad | Director | 2025-09-16 | D | 245,486 | 9 | 2,111,180 | Common | Form 4 ↗ |
| Thomas Gad | Director | 2025-09-16 | D | 130,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Thomas Gad | Director | 2025-09-16 | D | 60,235 | — | — | Common | Form 4 ↗ |
| Laura J. Hamill | Director | 2025-09-16 | D | 33,450 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Laura J. Hamill | Director | 2025-09-16 | D | 14,545 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Laura J. Hamill | Director | 2025-09-16 | D | 13,950 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Laura J. Hamill | Director | 2025-09-16 | D | 16,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Laura J. Hamill | Director | 2025-09-16 | D | 11,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Laura J. Hamill | Director | 2025-09-16 | D | 27,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Laura J. Hamill | Director | 2025-09-16 | D | 25,080 | — | — | Common | Form 4 ↗ |
| Peter Pfreundschuh | EVP, CFO and Treasurer | 2025-09-16 | D | 15,900 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Peter Pfreundschuh | EVP, CFO and Treasurer | 2025-09-16 | D | 63,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Peter Pfreundschuh | EVP, CFO and Treasurer | 2025-09-16 | D | 170,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Peter Pfreundschuh | EVP, CFO and Treasurer | 2025-09-16 | D | 77,800 | — | — | Common | Form 4 ↗ |
| Peter Pfreundschuh | EVP, CFO and Treasurer | 2025-09-16 | D | 15,900 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James I. Healy | Director | 2025-09-16 | D | 16,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David N. Gill | Director | 2025-09-16 | D | 33,450 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David N. Gill | Director | 2025-09-16 | D | 14,545 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David N. Gill | Director | 2025-09-16 | D | 13,950 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David N. Gill | Director | 2025-09-16 | D | 16,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David N. Gill | Director | 2025-09-16 | D | 11,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David N. Gill | Director | 2025-09-16 | D | 11,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David N. Gill | Director | 2025-09-16 | D | 16,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David N. Gill | Director | 2025-09-16 | D | 24,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David N. Gill | Director | 2025-09-16 | D | 25,080 | — | — | Common | Form 4 ↗ |
| David N. Gill | Director | 2025-09-16 | D | 5,825 | 9 | 50,095 | Common | Form 4 ↗ |
| Michael Rossi | Director | 2025-09-16 | D | 52,650 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Rossi | Director | 2025-09-16 | D | 18,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Rossi | Director | 2025-09-16 | D | 210,700 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Rossi | Director | 2025-09-16 | D | 214,200 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Rossi | Director | 2025-09-16 | D | 615,240 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James I. Healy | Director | 2025-09-16 | D | 25,080 | — | — | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (155 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Michael Rossi. DEF 14A, filed 2025-05-30. Section “Executive Compensation”. As printed: 4,557,590. View filing ↗
- Section 01, Peter Pfreundschuh. DEF 14A, filed 2025-05-30. Section “Executive Compensation”. As printed: 2,504,717. View filing ↗
- Section 01, Thomas Gad. DEF 14A, filed 2025-05-30. Section “Executive Compensation”. As printed: 2,075,163. View filing ↗
- Section 08, Mary Tagliaferri. DEF 14A, filed 2025-05-30. Section “Director Compensation”. As printed: 602,497. View filing ↗
- Section 08, James I. Healy. DEF 14A, filed 2025-05-30. Section “Director Compensation”. As printed: 262,792. View filing ↗
- Section 08, David N. Gill. DEF 14A, filed 2025-05-30. Section “Director Compensation”. As printed: 250,292. View filing ↗
- Section 08, Laura J. Hamill. DEF 14A, filed 2025-05-30. Section “Director Compensation”. As printed: 237,792. View filing ↗
- Section 08, Ashutosh Tyagi. DEF 14A, filed 2025-05-30. Section “Director Compensation”. As printed: 227,792. View filing ↗
- Section 08, Johan Wedell-Wedellsborg. DEF 14A, filed 2025-05-30. Section “Director Compensation”. As printed: 227,792. View filing ↗
- Section 08, Dr. Gérard Ber. DEF 14A, filed 2025-05-30. Section “Director Compensation”. As printed: 40,061. View filing ↗
- Section 08, Thomas Gad. DEF 14A, filed 2025-05-30. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Michael Rossi. DEF 14A, filed 2025-05-30. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Thomas Gad 2025-06-03. Form 4, filed 2025-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas Gad 2025-06-03. Form 4, filed 2025-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ashutosh Tyagi 2025-06-30. Form 4, filed 2025-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ashutosh Tyagi 2025-06-30. Form 4, filed 2025-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James I. Healy 2025-06-30. Form 4, filed 2025-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Johan Wedell-Wedellsborg 2025-06-30. Form 4, filed 2025-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David N. Gill 2025-06-30. Form 4, filed 2025-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David N. Gill 2025-06-30. Form 4, filed 2025-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James I. Healy 2025-06-30. Form 4, filed 2025-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Johan Wedell-Wedellsborg 2025-06-30. Form 4, filed 2025-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Laura J. Hamill 2025-06-30. Form 4, filed 2025-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Laura J. Hamill 2025-06-30. Form 4, filed 2025-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Rossi 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ashutosh Tyagi 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ashutosh Tyagi 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Rossi 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James I. Healy 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James I. Healy 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James I. Healy 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James I. Healy 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James I. Healy 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James I. Healy 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James I. Healy 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James I. Healy 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James I. Healy 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John LaRocca 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John LaRocca 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John LaRocca 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Johan Wedell-Wedellsborg 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Johan Wedell-Wedellsborg 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Johan Wedell-Wedellsborg 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Johan Wedell-Wedellsborg 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Johan Wedell-Wedellsborg 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Johan Wedell-Wedellsborg 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Johan Wedell-Wedellsborg 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Johan Wedell-Wedellsborg 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Johan Wedell-Wedellsborg 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Johan Wedell-Wedellsborg 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Johan Wedell-Wedellsborg 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Johan Wedell-Wedellsborg 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joris Wilms 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joris Wilms 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joris Wilms 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joris Wilms 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joris Wilms 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joris Wilms 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Laura J. Hamill 2025-09-16. Form 4, filed 2025-09-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joris Wilms 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Rossi 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Rossi 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Rossi 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas Gad 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ashutosh Tyagi 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ashutosh Tyagi 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ashutosh Tyagi 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ashutosh Tyagi 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ashutosh Tyagi 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Douglas J. Gentilcore 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Biotech ApS WG 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joris Wilms 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joris Wilms 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joris Wilms 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joris Wilms 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joris Wilms 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joris Wilms 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ashutosh Tyagi 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ashutosh Tyagi 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ashutosh Tyagi 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas Gad 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas Gad 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas Gad 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas Gad 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas Gad 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas Gad 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas Gad 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas Gad 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas Gad 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas Gad 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas Gad 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas Gad 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas Gad 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas Gad 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas Gad 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas Gad 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas Gad 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Laura J. Hamill 2025-09-16. Form 4, filed 2025-09-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Laura J. Hamill 2025-09-16. Form 4, filed 2025-09-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Laura J. Hamill 2025-09-16. Form 4, filed 2025-09-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Laura J. Hamill 2025-09-16. Form 4, filed 2025-09-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Laura J. Hamill 2025-09-16. Form 4, filed 2025-09-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Laura J. Hamill 2025-09-16. Form 4, filed 2025-09-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Laura J. Hamill 2025-09-16. Form 4, filed 2025-09-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Peter Pfreundschuh 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Peter Pfreundschuh 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Peter Pfreundschuh 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Peter Pfreundschuh 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Peter Pfreundschuh 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James I. Healy 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David N. Gill 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David N. Gill 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David N. Gill 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David N. Gill 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David N. Gill 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David N. Gill 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David N. Gill 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David N. Gill 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David N. Gill 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David N. Gill 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Rossi 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Rossi 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Rossi 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Rossi 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Rossi 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James I. Healy 2025-09-16. Form 4, filed 2025-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-07-15. Item 5.07 · say-on-pay result. As reported: 87.56% (votes for as printed: 27,011,027). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-13. Item 5.07 · say-on-pay result. As reported: 97.47% (votes for as printed: 27,772,834). View filing ↗
- Section 06, 2023 vote. Form 8-K, filed 2023-06-09. Item 5.07 · say-on-pay result. As reported: 72.65% (votes for as printed: 15,934,564). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 438,862 + equity 326,829 + all other 0 = 765,691, summed across the director compensation table rows.
- Rhythm Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Rhythm Pharmaceuticals, Inc.'s own proxy. As printed: 17,544,525. View filing ↗
- SpringWorks Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-04. CEO total compensation as printed in SpringWorks Therapeutics, Inc.'s own proxy. As printed: 16,153,317. View filing ↗
- BioCryst Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in BioCryst Pharmaceuticals, Inc.'s own proxy. As printed: 12,951,082. View filing ↗
- Arcus Biosciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Arcus Biosciences, Inc.'s own proxy. As printed: 9,656,813. View filing ↗
- Travere Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Travere Therapeutics, Inc.'s own proxy. As printed: 8,457,151. View filing ↗
- Deciphera Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2024-04-25. CEO total compensation as printed in Deciphera Pharmaceuticals, Inc.'s own proxy. As printed: 6,010,712. View filing ↗
- Agios Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Agios Pharmaceuticals, Inc.'s own proxy. As printed: 5,370,389. View filing ↗
- Rigel Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-03. CEO total compensation as printed in Rigel Pharmaceuticals, Inc.'s own proxy. As printed: 4,658,805. View filing ↗
- Y-mAbs Therapeutics, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2025-05-30. CEO total compensation as printed in Y-mAbs Therapeutics, Inc.'s own proxy. As printed: 4,557,590. View filing ↗
- UroGen Pharma Ltd., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in UroGen Pharma Ltd.'s own proxy. As printed: 4,310,624. View filing ↗
- Heron Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Heron Therapeutics, Inc.'s own proxy. As printed: 3,516,291. View filing ↗
- Aadi Bioscience, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Aadi Bioscience, Inc.'s own proxy. As printed: 3,359,075. View filing ↗
- G1 Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2024-04-25. CEO total compensation as printed in G1 Therapeutics, Inc.'s own proxy. As printed: 3,250,658. View filing ↗
- Puma Biotechnology, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Puma Biotechnology, Inc.'s own proxy. As printed: 3,062,337. View filing ↗
- bluebird bio, Inc., Section 10b CEO total. DEF 14A, filed 2024-09-26. CEO total compensation as printed in bluebird bio, Inc.'s own proxy. As printed: 3,049,181. View filing ↗
- Karyopharm Therapeutics Inc., Section 10b CEO total. DEF 14A, filed 2026-04-13. CEO total compensation as printed in Karyopharm Therapeutics Inc.'s own proxy. As printed: 2,320,902. View filing ↗
- MacroGenics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-08. CEO total compensation as printed in MacroGenics, Inc.'s own proxy. As printed: 2,078,854. View filing ↗
- Iovance Biotherapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Iovance Biotherapeutics, Inc.'s own proxy. As printed: 1,888,175. View filing ↗
- Atara Biotherapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Atara Biotherapeutics, Inc.'s own proxy. As printed: 1,068,069. View filing ↗
- Section 10a, G1 Therapeutics, Inc. reciprocity. DEF 14A. G1 Therapeutics, Inc. names Y-mAbs Therapeutics, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Deciphera Pharmaceuticals, Inc. reciprocity. DEF 14A. Deciphera Pharmaceuticals, Inc. names Y-mAbs Therapeutics, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Heron Therapeutics, Inc. reciprocity. DEF 14A. Heron Therapeutics, Inc. names Y-mAbs Therapeutics, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, MacroGenics, Inc. reciprocity. DEF 14A. MacroGenics, Inc. names Y-mAbs Therapeutics, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, UroGen Pharma Ltd. reciprocity. DEF 14A. UroGen Pharma Ltd. names Y-mAbs Therapeutics, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗